Videos

MRD can prove useful in the treatment of patients with hairy cell leukemia who relapsed.

For patients with hairy cell leukemia, it's complications after treatment that can be life-threatening.

At the 2019 Hairy Cell Leukemia Foundation Annual Conference new findings showed promise in the safety of vemurafenib to treat patients with hairy cell leukemia.

Chemotherapy is often associated with devastating toxicities, but moxetumomab pasudotox appears to be manageable based on the findings from a new trial.

One expert details why axillary lymph node dissection is vital in the treatment of patients with breast cancer.

Patients with the highest risk of developing a BRCA mutation are not being tested earlier enough and developing these mutations when it's too late. Clinicians can change that.

The future of treating patients with triple-negative breast cancer is bright, but more needs to be done to address mutations early on in the course of the disease.

Overall survival results from the MONALESSA-3 phase III trial showed positive results for patients with advanced breast cancer, but toxicities related to the use of ribociclib still need to be addressed.

Experts are looking to use immunotherapy in different ways for patients with early-stage breast cancer.

Results from the randomized phase 3 POLO trial are in, and the quality of life data shows promise for patients with metastatic pancreatic cancer who harbor a germline BRCA gene mutation.

Advanced ovarian cancer is deadly for female patients with the disease, but results from a new study show promise for a new frontline treatment.

For patients with breast cancer with a PDL1 expression, a new treatment targeting immune cells could make a major difference.

While the findings from the most recent CARD study prove promising, it's the toxicity results that have one expert excited.

For patients with advanced prostate cancer, new findings from the CARD trial could change their daily treatment.

When patients with MCL develop resistance to chemotherapy and targeted therapies, experts believe CAR T-cell therapy can step in.

CAR T-cell therapies are a revolutionary form of treatment for patients with cancer, but it does come with its unique adverse events.

CAR T-cell therapy is changing the landscape of cancer care, but challenges for certain cancer types still remain.

Pediatric patients with ALL can expect therapies to help target their disease after they relapse, but experts are looking to combat the disease in the frontline before that.

About a third of breast cancer survivors are still living with fatigue and reduced exercise capacity after treatment ends.

When patients are experiencing cancer-related fatigue, oncology nurses might want to consider referring them to cognitive behavior therapy (CBT).

While some view immunotherapy as limiting in small-cell lung cancer treatment, one expert believes otherwise.

Financial toxicity can have an impact on patients' anxiety and depression, but oncology nurses can help.

While treatment options for lung cancer have vastly improved over the last decade, attitudes toward the disease have actually gotten worse.

Due to their strict regulations, clinical trials eliminate room for discriminatory practices, and can lend insight to disparities among groups.

Don't waste time being upset, and don't try to shield loved ones from their diagnosis.

From long-term data to additional clinical trials, more is needed to better understand immunotherapy in lung cancer.

An expert gives an overview of the different treatment approaches for patients with breast cancer that has metastasized to their brain.

It is crucial for nurses to be aware of adverse events that can occur in patients who are receiving CAR T-cell therapy, explained one expert.